Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Emerging Technologies for Pulmonary Vein Isolation

FD. Ramirez, VY. Reddy, R. Viswanathan, M. Hocini, P. Jaïs

. 2020 ; 127 (1) : 170-183. [pub] 20200618

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc21020447

Atrial fibrillation is the most common sustained cardiac arrhythmia and is associated with considerable morbidity and mortality. Electrically isolating the pulmonary veins from the left atrium by catheter ablation is superior to antiarrhythmic drug therapy for maintaining sinus rhythm, but its success varies depending on multiple factors, including arrhythmic burden. Although procedural outcomes have improved over the years, further gains are limited by a seemingly zero-sum relationship between effectiveness and safety, which is largely a product of the available technologies. Current energies used to create contiguous, transmural, and durable atrial lesions can result in serious complications if they reach the esophagus or phrenic nerve, for instance-structures that can be adjacent to the atrial myocardium, often within millimeters of the energy source. Consequently, high rates of pulmonary vein-left atrium reconnections are consistently seen in clinical studies and in clinical practice as operators appropriately forgo ablation effectiveness to protect patients from harm. However, as ablative technologies evolve to circumvent this stalemate, safer, and more effective pulmonary vein isolation seems increasingly realistic. Furthermore, the innovative nature of these technologies raises the prospect of markedly improved procedural efficiency, which could increase patient comfort, reduce operator occupational injuries, and enhance the use of health resources-all of which are increasingly important considerations particularly as the demand for catheter ablation for atrial fibrillation continues to rise. We herein review 3 promising candidate ablation technologies with the potential to revolutionize the management of patients with atrial fibrillation: electroporation (pulsed-field ablation), expandable lattice-tip radiofrequency ablation/electroporation, and ultra-low temperature cryoablation.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020447
003      
CZ-PrNML
005      
20210830102128.0
007      
ta
008      
210728s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1161/CIRCRESAHA.120.316402 $2 doi
035    __
$a (PubMed)32716722
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Ramirez, F Daniel $u From the University of Bordeaux, CHU Bordeaux, Bordeaux-Pessac, France (F.D.R., M.H., P.J.) $u IHU LIRYC ANR-10-IAHU-04, Equipex MUSIC ANR-11-EQPX-0030 (F.D.R., M.H., P.J.)
245    10
$a Emerging Technologies for Pulmonary Vein Isolation / $c FD. Ramirez, VY. Reddy, R. Viswanathan, M. Hocini, P. Jaïs
520    9_
$a Atrial fibrillation is the most common sustained cardiac arrhythmia and is associated with considerable morbidity and mortality. Electrically isolating the pulmonary veins from the left atrium by catheter ablation is superior to antiarrhythmic drug therapy for maintaining sinus rhythm, but its success varies depending on multiple factors, including arrhythmic burden. Although procedural outcomes have improved over the years, further gains are limited by a seemingly zero-sum relationship between effectiveness and safety, which is largely a product of the available technologies. Current energies used to create contiguous, transmural, and durable atrial lesions can result in serious complications if they reach the esophagus or phrenic nerve, for instance-structures that can be adjacent to the atrial myocardium, often within millimeters of the energy source. Consequently, high rates of pulmonary vein-left atrium reconnections are consistently seen in clinical studies and in clinical practice as operators appropriately forgo ablation effectiveness to protect patients from harm. However, as ablative technologies evolve to circumvent this stalemate, safer, and more effective pulmonary vein isolation seems increasingly realistic. Furthermore, the innovative nature of these technologies raises the prospect of markedly improved procedural efficiency, which could increase patient comfort, reduce operator occupational injuries, and enhance the use of health resources-all of which are increasingly important considerations particularly as the demand for catheter ablation for atrial fibrillation continues to rise. We herein review 3 promising candidate ablation technologies with the potential to revolutionize the management of patients with atrial fibrillation: electroporation (pulsed-field ablation), expandable lattice-tip radiofrequency ablation/electroporation, and ultra-low temperature cryoablation.
650    _2
$a zvířata $7 D000818
650    _2
$a fibrilace síní $x chirurgie $7 D001281
650    _2
$a katetrizační ablace $x metody $7 D017115
650    _2
$a lidé $7 D006801
650    _2
$a venae pulmonales $x chirurgie $7 D011667
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Reddy, Vivek Y $u Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, NY (V.Y.R.) $u Homolka Hospital, Prague, Czech Republic (V.Y.R.)
700    1_
$a Viswanathan, Raju $u Farapulse, Inc, Menlo Park, CA (R.V.)
700    1_
$a Hocini, Mélèze $u From the University of Bordeaux, CHU Bordeaux, Bordeaux-Pessac, France (F.D.R., M.H., P.J.) $u IHU LIRYC ANR-10-IAHU-04, Equipex MUSIC ANR-11-EQPX-0030 (F.D.R., M.H., P.J.)
700    1_
$a Jaïs, Pierre $u From the University of Bordeaux, CHU Bordeaux, Bordeaux-Pessac, France (F.D.R., M.H., P.J.) $u IHU LIRYC ANR-10-IAHU-04, Equipex MUSIC ANR-11-EQPX-0030 (F.D.R., M.H., P.J.)
773    0_
$w MED00001092 $t Circulation research $x 1524-4571 $g Roč. 127, č. 1 (2020), s. 170-183
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32716722 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830102128 $b ABA008
999    __
$a ok $b bmc $g 1691091 $s 1140893
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 127 $c 1 $d 170-183 $e 20200618 $i 1524-4571 $m Circulation research $n Circ Res $x MED00001092
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...